Disclosed is a method for moisturizing skin in need thereof, the method comprising topically applying to the skin a composition that includes effective amounts of an extract from Echinacea purpurea, an extract from Silybum marianum, and glycerin, wherein topical application of the composition activates human cannabinoid receptor type 2 and inhibits fatty acid amide hydrolase activity in the skin and treats the skin.

Disclosed is a method for moisturizing skin in need thereof, the method comprising topically applying to the skin a composition that includes effective amounts of an extract from Echinacea purpurea, an extract from Silybum marianum, and glycerin, wherein topical application of the composition activates human cannabinoid receptor type 2 and inhibits fatty acid amide hydrolase activity in the skin and treats the skin.

Disclosed is a method for moisturizing skin in need thereof, the method comprising topically applying to the skin a composition that includes effective amounts of an extract from Echinacea purpurea, an extract from Silybum marianum, and glycerin, wherein topical application of the composition activates human cannabinoid receptor type 2 and inhibits fatty acid amide hydrolase activity in the skin and treats the skin.

A method for reducing muscle contraction of a facial muscle or reducing the appearance of a fine line or wrinkle is disclosed. The method can include topical application of a composition to facial skin and/or to the fine line or wrinkle. The composition can include an effective amount of Rosmarinus officinalis leaf extract, an effective amount of Lavendula stoechas extract, and an effective amount of Acmella oleracea extract. Topical application of the composition to facial skin can reduce muscle contraction of the facial muscle. Topical application of the composition to the fine line or wrinkle can reduce the appearance of the fine line or wrinkle.

A method for reducing muscle contraction of a facial muscle or reducing the appearance of a fine line or wrinkle is disclosed. The method can include topical application of a composition to facial skin and/or to the fine line or wrinkle. The composition can include an effective amount of Rosmarinus officinalis leaf extract, an effective amount of Lavendula stoechas extract, and an effective amount of Acmella oleracea extract. Topical application of the composition to facial skin can reduce muscle contraction of the facial muscle. Topical application of the composition to the fine line or wrinkle can reduce the appearance of the fine line or wrinkle.

A method of producing an extract of an animal-derived or plant-derived biological material includes: extracting a component in the biological material using liquefied dimethyl ether for the biological material to obtain a liquefied dimethyl ether solution including the component; separating the solution from the biological material; and volatilizing or separating the liquefied dimethyl ether from the solution.

The present invention relates to the combination of a retinoid and an extract of Silybum marianum (L.) Gaertn., the dermatological and dermocosmetic compositions containing such a combination, as well as their uses as a medicinal product, in particular in the treatment of acne, seborrhea, seborrhoeic dermatitis and/or rosacea.

The present invention relates to the combination of a retinoid and an extract of Silybum marianum (L.) Gaertn., the dermatological and dermocosmetic compositions containing such a combination, as well as their uses as a medicinal product, in particular in the treatment of acne, seborrhea, seborrhoeic dermatitis and/or rosacea.

The present invention relates to the combination of a retinoid and an extract of Silybum marianum (L.) Gaertn., the dermatological and dermocosmetic compositions containing such a combination, as well as their uses as a medicinal product, in particular in the treatment of acne, seborrhea, seborrhoeic dermatitis and/or rosacea.

An oral pharmabiotic system is disclosed for improving oral, dental, and systemic health by repopulating and reshaping the flora within a patient's oral environment in a manner that overcomes the deficiencies of prior oral probiotic products. By formulating the pharmabiotic system as a strip for adhesive placement within a patients' oral cavity, preferably against the buccal mucosa, alveolar mucosa, oral labial mucosa, or a dental appliance, and configuring the parameters of the strip such that neither disadhesion nor complete dissolution occurs for at least a period of at least three hours during daytime use and at least six hours during nighttime use, the probiotic payload contained within may remain in the oral cavity for a sufficient length of time required for the probiotics to activate, replicate, and displace existing harmful oral pathobiotics.